BRPI0314377B8 - composto, composição farmacêutica, tablete ou cápsula, uso de uma quantidade terapeuticamente eficaz, e, processo para preparar um composto - Google Patents
composto, composição farmacêutica, tablete ou cápsula, uso de uma quantidade terapeuticamente eficaz, e, processo para preparar um compostoInfo
- Publication number
- BRPI0314377B8 BRPI0314377B8 BRPI0314377A BR0314377A BRPI0314377B8 BR PI0314377 B8 BRPI0314377 B8 BR PI0314377B8 BR PI0314377 A BRPI0314377 A BR PI0314377A BR 0314377 A BR0314377 A BR 0314377A BR PI0314377 B8 BRPI0314377 B8 BR PI0314377B8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- preparing
- capsule
- tablet
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 239000002775 capsule Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003826 tablet Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 4
- SRPXSILJHWNFMK-UHFFFAOYSA-N norsertraline Chemical compound C12=CC=CC=C2C(N)CCC1C1=CC=C(Cl)C(Cl)=C1 SRPXSILJHWNFMK-UHFFFAOYSA-N 0.000 abstract 3
- 208000015114 central nervous system disease Diseases 0.000 abstract 2
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- QTQHFJQQMCUQEY-UHFFFAOYSA-N n-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide Chemical class C1=C(Cl)C(Cl)=CC=C1C1C2=CC=CC=C2C(NC=O)CC1 QTQHFJQQMCUQEY-UHFFFAOYSA-N 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
- C07C2602/28—Hydrogenated naphthalenes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41130502P | 2002-09-16 | 2002-09-16 | |
| US41130402P | 2002-09-16 | 2002-09-16 | |
| US60/411,304 | 2002-09-16 | ||
| US60/411,305 | 2002-09-16 | ||
| PCT/US2003/029110 WO2004024669A1 (en) | 2002-09-16 | 2003-09-16 | Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0314377A BR0314377A (pt) | 2005-07-19 |
| BRPI0314377B1 BRPI0314377B1 (pt) | 2020-11-24 |
| BRPI0314377B8 true BRPI0314377B8 (pt) | 2021-05-25 |
Family
ID=31998027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0314377A BRPI0314377B8 (pt) | 2002-09-16 | 2003-09-16 | composto, composição farmacêutica, tablete ou cápsula, uso de uma quantidade terapeuticamente eficaz, e, processo para preparar um composto |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US7087785B2 (https=) |
| EP (1) | EP1542961B1 (https=) |
| JP (1) | JP4610336B2 (https=) |
| KR (2) | KR101067045B1 (https=) |
| CN (1) | CN101712626B (https=) |
| AU (1) | AU2003272460B2 (https=) |
| BR (1) | BRPI0314377B8 (https=) |
| CA (1) | CA2498152C (https=) |
| DK (1) | DK1542961T3 (https=) |
| ES (1) | ES2431519T3 (https=) |
| IL (1) | IL167319A (https=) |
| MX (1) | MXPA05002700A (https=) |
| NZ (1) | NZ538741A (https=) |
| PT (1) | PT1542961E (https=) |
| WO (1) | WO2004024669A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0314377B8 (pt) * | 2002-09-16 | 2021-05-25 | Sepracor Inc | composto, composição farmacêutica, tablete ou cápsula, uso de uma quantidade terapeuticamente eficaz, e, processo para preparar um composto |
| US8134029B2 (en) | 2002-09-16 | 2012-03-13 | Sunovion Pharmaceuticals Inc. | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine |
| US20050176680A1 (en) * | 2003-12-11 | 2005-08-11 | Sepracor, Inc. | Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
| JP2007517056A (ja) * | 2003-12-29 | 2007-06-28 | セプラコア インコーポレーテッド | ピロール及びピラゾールｄａａｏ阻害剤 |
| US20060199739A1 (en) * | 2005-03-02 | 2006-09-07 | Olav Messerschmidt | Limonene-containing herbicide compositions, herbicide concentrate formulations and methods for making and using same |
| EP2455075B1 (en) * | 2005-07-06 | 2018-06-20 | Sunovion Pharmaceuticals Inc. | Process for Preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine |
| JP2009522721A (ja) * | 2005-12-29 | 2009-06-11 | ユーティーシー パワー コーポレイション | ガス輸送式燃料電池冷媒の循環 |
| NZ569608A (en) * | 2006-01-06 | 2011-09-30 | Sepracor Inc | Tetralone-based monoamine reuptake inhibitors |
| US20070203111A1 (en) | 2006-01-06 | 2007-08-30 | Sepracor Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
| CN101421228B (zh) * | 2006-03-31 | 2014-05-21 | 塞普拉柯公司 | 手性酰胺和胺的制备 |
| AU2013211500B2 (en) * | 2006-03-31 | 2016-08-04 | Sepracor Inc | Preparation of chiral amides and amines |
| EP2043745A2 (en) * | 2006-05-31 | 2009-04-08 | SEPRACOR Inc | Treatment of pain disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine and its formamide |
| US7579370B2 (en) * | 2006-06-30 | 2009-08-25 | Sepracor Inc. | Fused heterocycles |
| US7884124B2 (en) * | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| BRPI0717171B1 (pt) * | 2006-09-25 | 2023-10-17 | Archer Daniels Midland Company | Material superabsorvente |
| US20080082066A1 (en) * | 2006-10-02 | 2008-04-03 | Weyerhaeuser Co. | Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks |
| US8138377B2 (en) * | 2006-11-07 | 2012-03-20 | Dov Pharmaceutical, Inc. | Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use |
| FR2909376A1 (fr) * | 2006-11-30 | 2008-06-06 | Cerep Sa | Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables |
| CA2676432A1 (en) * | 2007-01-18 | 2008-07-24 | Sepracor, Inc. | Inhibitors of d-amino acid oxidase |
| US7902252B2 (en) * | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| CA2688493C (en) | 2007-05-31 | 2016-04-19 | Sepracor Inc. | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
| US20100120740A1 (en) * | 2008-08-07 | 2010-05-13 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| CN102573823B (zh) * | 2009-05-13 | 2015-01-07 | 桑诺维恩药品公司 | 包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途 |
| US20110034434A1 (en) * | 2009-08-07 | 2011-02-10 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| WO2011069032A2 (en) * | 2009-12-04 | 2011-06-09 | Sunovion Pharmaceuticals Inc. | Formulations, salts and polymorphs of transnorsertraline and uses thereof |
| US10085414B2 (en) | 2011-05-19 | 2018-10-02 | Gilrose Pharmaceuticals, Llc | Pre-frontal cortex processing disorder speech, gait and limb impairments treatment |
| US9220712B2 (en) | 2011-05-19 | 2015-12-29 | Gilrose Pharmaceuticals, Llc | Pharmaceutical intervention and method for treating an apraxia of speech in children |
| US9682073B2 (en) | 2011-05-19 | 2017-06-20 | Gilrose Pharmaceuticals, Llc | Pre-frontal cortex processing disorder gait and limb impairments treatment |
| US20140163070A1 (en) | 2012-05-17 | 2014-06-12 | Bruce Roseman | Treatment for cerebral palsy impaired speech in children |
| WO2012158892A2 (en) | 2011-05-19 | 2012-11-22 | Bruce Roseman | A method of treating apraxia of speech in children |
| US8883815B2 (en) | 2011-05-19 | 2014-11-11 | Gilrose Pharmaceuticals, Llc | Treatment for cerebral palsy impaired speech in children |
| AU2015259337A1 (en) * | 2014-05-13 | 2016-12-08 | Sunovion Pharmaceuticals Inc. | Methods and compositions of dasotraline for treatment of ADHD |
| JP2017515849A (ja) * | 2014-05-13 | 2017-06-15 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | Ａｄｈｄを治療するためのダソトラリン用量および治療方法 |
| WO2016046669A2 (en) * | 2014-09-27 | 2016-03-31 | Mohan M Alapati | Compositions and methods for the treatment of depression and neurological diseases |
| US20200405867A1 (en) | 2018-01-19 | 2020-12-31 | Sunovion Pharmaceuticals Inc. | Oral dosage forms |
| WO2020092496A1 (en) | 2018-10-31 | 2020-05-07 | Sunovion Pharmaceuticals Inc. | Methods of treating central nervous system disorders |
| EP3800178A1 (en) | 2019-10-01 | 2021-04-07 | Moehs Ibérica, S.L. | Preparation of enamide intermediate for the synthesis of dasotraline |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59497B2 (ja) * | 1979-11-01 | 1984-01-07 | フアイザ−・インコ−ポレ−テツド | トランス−４−フエニル−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの抗抑うつ性誘導体 |
| US4556676A (en) * | 1979-11-01 | 1985-12-03 | Pfizer Inc. | Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| US4981870A (en) * | 1989-03-07 | 1991-01-01 | Pfizer Inc. | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
| US5554383A (en) | 1995-04-06 | 1996-09-10 | Trustees Of Tufts College | Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression |
| US5778986A (en) * | 1997-08-05 | 1998-07-14 | Davis; Floyd A. | Device to remove divots |
| US6245782B1 (en) | 1999-05-17 | 2001-06-12 | Heartdrug Research L.L.C. | Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors |
| BRPI0314377B8 (pt) * | 2002-09-16 | 2021-05-25 | Sepracor Inc | composto, composição farmacêutica, tablete ou cápsula, uso de uma quantidade terapeuticamente eficaz, e, processo para preparar um composto |
-
2003
- 2003-09-16 BR BRPI0314377A patent/BRPI0314377B8/pt not_active IP Right Cessation
- 2003-09-16 US US10/663,173 patent/US7087785B2/en not_active Expired - Lifetime
- 2003-09-16 MX MXPA05002700A patent/MXPA05002700A/es active IP Right Grant
- 2003-09-16 WO PCT/US2003/029110 patent/WO2004024669A1/en not_active Ceased
- 2003-09-16 ES ES03754641T patent/ES2431519T3/es not_active Expired - Lifetime
- 2003-09-16 NZ NZ538741A patent/NZ538741A/en not_active IP Right Cessation
- 2003-09-16 EP EP03754641.3A patent/EP1542961B1/en not_active Expired - Lifetime
- 2003-09-16 CN CN2009102541788A patent/CN101712626B/zh not_active Expired - Fee Related
- 2003-09-16 JP JP2004536572A patent/JP4610336B2/ja not_active Expired - Fee Related
- 2003-09-16 DK DK03754641.3T patent/DK1542961T3/da active
- 2003-09-16 PT PT37546413T patent/PT1542961E/pt unknown
- 2003-09-16 KR KR1020057004420A patent/KR101067045B1/ko not_active Expired - Fee Related
- 2003-09-16 AU AU2003272460A patent/AU2003272460B2/en not_active Ceased
- 2003-09-16 KR KR1020117017571A patent/KR101165549B1/ko not_active Expired - Fee Related
- 2003-09-16 CA CA2498152A patent/CA2498152C/en not_active Expired - Fee Related
-
2005
- 2005-03-08 IL IL167319A patent/IL167319A/en active IP Right Grant
- 2005-09-07 US US11/220,891 patent/US7105699B2/en not_active Expired - Lifetime
-
2006
- 2006-01-24 US US11/338,191 patent/US20060128993A1/en not_active Abandoned
- 2006-05-03 US US11/416,586 patent/US7423179B2/en not_active Expired - Lifetime
-
2008
- 2008-07-15 US US12/173,626 patent/US7589237B2/en not_active Expired - Lifetime
-
2009
- 2009-08-10 US US12/538,583 patent/US7790772B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0314377B8 (pt) | composto, composição farmacêutica, tablete ou cápsula, uso de uma quantidade terapeuticamente eficaz, e, processo para preparar um composto | |
| BR0309875A (pt) | métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto | |
| BRPI0411508A (pt) | composto, formulação farmacêutica, uso de um composto, método para tratar doenças, e, processo para preparar um composto | |
| BR9807673A (pt) | Processos para tratar asma alérgica e dermatite em um humano e composição farmacêutica. | |
| BRPI0411255A (pt) | composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
| BR0214967A (pt) | Composto, sal famaceuticamente aceitável, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratar um distúrbio de um paciente | |
| BR0308739A (pt) | Tratamentos em combinação para doenças mediadas por quimiocina | |
| NO983612L (no) | Nye cykliske aminosyrer som farmas°ytiske midler | |
| DE60216830D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen | |
| IS4819A (is) | Nýstárlegar staðgengnar hringamínósýrur notaðar til lyfjagerðar | |
| BR0206435A (pt) | Composto, composição farmacêutica, métodos de tratar a angiogênese em um paciente, de tratar distúrbios relacionados com kdr e proliferativos em um mamìfero, uso de um composto, e, processo para preparar compostos | |
| BR0312722A (pt) | Derivados de pirazol heterobicìclico como inibidores de qinase | |
| AP2002002517A0 (en) | Bicyclic amino acids as pharmaceutical agents. | |
| BR0104830A (pt) | Tratamento de combinação para a demência ou déficits cognitivos associados com a doença de alzheimer e com a doença de parkinson | |
| NO306779B1 (no) | Naftalamider, anvendelse derav og farmasöytisk preparat | |
| BRPI0411936A (pt) | composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade | |
| BR0313718A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto | |
| CA2214026A1 (en) | Pharmaceutical compositions comprising monoamine oxidase b inhibitors | |
| BR9910130A (pt) | Derivados de cubana como antagonistas de receptor de glutamato metabotrópico e processo para a sua preparação | |
| BR9809234A (pt) | Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo. | |
| WO2007143267A3 (en) | Treatment of pain disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine and its formamide | |
| BRPI0410654A (pt) | composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
| BR9406923A (pt) | Compostos derivados de (1-heteroazolil-1-heterociclil)alcano processo para preparar os mesmos formulaçao farmaceutica uso de compostos e processo para o tratamento de disturbios neuropsiquiatricos cronicos e agudos | |
| BR0111897A (pt) | Composto, método para tratar um indivìduo afligido por alguns distúrbios dos sistemas nervosos periférico e central, composição farmacêutica, e, uso de um composto | |
| RU94040886A (ru) | Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: PARA:INT.CI. A61K 31/135, A61K 9/20, A61K 9/48, A61P 25/00, A61P 25/06, A61P 25/08, A61P 25/14, A61P 25/16, A61P 25/20, A61P 25/22, A61P 25/24, A61P 25/28, A61P 25/30, C07C 209/62, C07C 211/42 Ipc: A61K 31/135 (2011.01), A61K 9/20 (2011.01), A61K 9 |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: C07C 211/42 (2006.01), C07C 209/62 (2006.01), A61K |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/09/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 20A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2740 DE 11-07-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |